DNA damage response gene alterations in urothelial cancer: ready for practice?

Cisplatin-based neoadjuvant chemotherapy prior to radical cystectomy is standard in fit patients. Inactivating mutations of the nucleotide excision repair gene, ERCC2, can predict response to cisplatin-based chemotherapy. Evaluation of the functional impact of ERCC2 mutations can provide mechanistic frameworks supporting the potential predictive role of ERCC2 loss of function.

https://ift.tt/2qWZWoM